


AMENDMENTS TO THE CLAIMS

This listing of claims will replace all prior versions, and listings, of claims in the application.

Listing of claims:

1. (Currently Amended) A compound of Formula (I)



(I)

or a stereoisomer or a pharmaceutically acceptable salt thereof, wherein:

Z is selected from a bond, -NR¹⁸C(O)- or -NR¹⁸C(S)-, -NR¹⁸C(O)NH-, -NR¹⁸C(S)NH-,
-NR¹⁸SO₂-, -NR¹⁸SO₂NH-, C(O)NR¹⁸-, OC(O)NR¹⁸-, NR¹⁸C(O)O-, (CR²⁵R²⁵)_t-,
-CR²⁴=CR²⁴-, CR²⁵R²⁵C(O)-, C(O)CR²⁵R²⁵-, CR²⁵R²⁵C(-N OR²⁶)-, O-CR²⁴R²⁴-,
-C R²⁴R²⁴-O-, O-, NR¹⁹-, NR¹⁹-CR²⁴R²⁴-, CHR²⁴-NR¹⁹-, S(O)_p-,
-S(O)_p-CR²⁴R²⁴-, and -S(O)_p-NR¹⁹-;

~~Q is selected from O or S;~~

wherein neither Z nor R¹³ are connected to a carbon atom labeled (b);

X is selected from ~~NR¹⁷~~ and ~~-CHR¹⁶NR¹⁷~~;

bond (a) is a single or double bond;

~~alternatively, when n is equal to 2, two atoms labeled (b) may join through a double bond:~~

R^1 is selected from a C_{6-10} aryl group substituted with 0-5 R^4 and a 5-10 membered heteroaryl system containing 1-4 heteroatoms selected from N, O, and S, substituted with 0-3 R^4 ;

R^2 is selected from a C_{6-10} aryl group substituted with 0-5 R^5 and a 5-10 membered heteroaryl system containing 1-4 heteroatoms selected from N, O, and S, substituted with 0-3 R^5 ;

R^3 is selected from H, $(CRR)_qOH$, $(CRR)_qSH$, $(CRR)_qOR^{3d}$, $(CRR)_qS(O)_pR^{3d}$, $(CRR)_rC(O)R^{3b}$, $(CRR)_qNR^{3a}R^{3a}$, $(CRR)_rC(O)NR^{3a}R^{3a}$, $(CRR)_rC(O)NR^{3a}OR^{3d}$, $(CRR)_qSO_2NR^{3a}R^{3a}$, $(CRR)_rC(O)OR^{3d}$, a $(CRR)_rC_{3-10}$ carbocyclic residue substituted with 0-5 R^{3c} , and a $(CRR)_r$ -5-10 membered heterocyclic system containing 1-4 heteroatoms selected from N, O, and S, substituted with 0-3 R^{3c} ;

with the proviso that R^3 is not H if R^6 is H;

alternatively, R^3 and R^{12} join to form a C_{3-6} cycloalkyl substituted with 0-2 R^{3g} , a 5-6 membered lactam ring in which carbon atoms of the ring are substituted with 0-2 R^{3g} , or a 5-6 membered lactone ring in which carbon atoms of the ring are substituted with 0-2 R^{3g} ;

R^{3a} , at each occurrence, is independently selected from H, methyl substituted with 0-1 R^{3c} , C_{2-6} alkyl substituted with 0-3 R^{3c} , C_{3-8} alkenyl substituted with 0-3 R^{3c} , C_{3-8} alkynyl substituted with 0-3 R^{3c} , $(CH_2)_rC_{3-6}$ cycloalkyl, a $(CH_2)_rC_{3-10}$ carbocyclic residue substituted with 0-5 R^{3c} , and a $(CH_2)_r$ -5-10 membered heterocyclic system containing 1-4 heteroatoms selected from N, O, and S, substituted with 0-3 R^{3c} ;

R^{3b} , at each occurrence, is independently selected from C_{1-6} alkyl substituted with 0-3 R^{3c} , C_{2-8} alkenyl substituted with 0-3 R^{3c} , C_{2-8} alkynyl substituted with 0-3 R^{3c} , a $(CH_2)_rC_{3-6}$ carbocyclic residue substituted with 0-2 R^{3c} , and a $(CH_2)_r$ -5-6 membered heterocyclic system containing 1-4 heteroatoms selected from N, O, and S, substituted with 0-3 R^{3c} ;

R^{3c} is independently selected from $-C(O)R^{3b}$, $-C(O)OR^{3d}$, $-C(O)NR^{3f}R^{3f}$, and $(CH_2)_r$ phenyl;

R^{3d} , at each occurrence, is independently selected from H, methyl, $-CF_3$, C_{2-6} alkyl substituted with 0-3 R^{3e} , C_{3-6} alkenyl substituted with 0-3 R^{3e} , C_{3-6} alkynyl substituted with 0-3 R^{3e} , a C_{3-10} carbocyclic residue substituted with 0-3 R^{3e} , and a $(CH_2)_5-6$ membered heterocyclic system containing 1-4 heteroatoms selected from N, O, and S, substituted with 0-3 R^{3e} ;

R^{3e} , at each occurrence, is selected from C_{1-6} alkyl, C_{2-8} alkenyl, C_{2-8} alkynyl, C_{3-6} cycloalkyl, Cl, F, Br, I, CN, NO_2 , $(CF_2)_tCF_3$, $(CH_2)_tOC_{1-5}$ alkyl, OH, SH, $(CH_2)_tSC_{1-5}$ alkyl, $(CH_2)_tNR^{3f}R^{3f}$, and $(CH_2)_t$ phenyl;

R^{3f} , at each occurrence, is selected from H, C_{1-6} alkyl, and C_{3-6} cycloalkyl;

R^{3g} is selected from $(CHR)_tOH$, $(CHR)_tSH$, $(CHR)_tOR^{3d}$, $(CHR)_tS(O)_tR^{3d}$, $(CHR)_tC(O)R^{3b}$, $(CHR)_tNR^{3a}R^{3a}$, $(CHR)_tC(O)NR^{3a}R^{3a}$, $(CHR)_tC(O)NR^{3a}OR^{3d}$, $(CHR)_tSO_2NR^{3a}R^{3a}$, $(CHR)_tC(O)OR^{3d}$, and a $(CHR)_tC_{3-10}$ carbocyclic residue substituted with 0-5 R^{3e} ;

R, at each occurrence, is independently selected from H, C_{1-6} alkyl, C_{2-8} alkenyl, C_{2-8} alkynyl, $(CH_2)_tC_{3-6}$ cycloalkyl, $(CHR)_tC(O)NR^{3a}R^{3a}$, and $(CHR)_tC(O)OR^{3d}$, and $(CH_2)_t$ phenyl substituted with 0-3 R^{3e} , and a $(CH_2)_t5-10$ membered heterocyclic system containing 1-4 heteroatoms selected from N, O, and S, substituted with 0-3 R^{3e} ;

R^4 , at each occurrence, is selected from C_{1-8} alkyl, C_{2-8} alkenyl, C_{2-8} alkynyl, $(CR'R')_tC_{3-6}$ cycloalkyl, Cl, Br, I, F, NO_2 , CN, $(CR'R')_tNR^{4a}R^{4a}$, $(CR'R')_tOH$, $(CR'R')_tOR^{4d}$, $(CR'R')_tSH$, $(CR'R')_tSR^{4d}$, $(CR'R')_tC(O)OH$, $(CR'R')_tC(O)R^{4b}$, $(CR'R')_tC(O)NR^{4a}R^{4a}$, $(CR'R')_tNR^{4f}C(O)R^{4b}$, $(CR'R')_tC(O)OR^{4d}$, $(CR'R')_tOC(O)R^{4b}$, $(CR'R')_tNR^{4f}C(O)OR^{4d}$, $(CR'R')_tOC(O)NR^{4a}R^{4a}$, $(CR'R')_tNR^{4a}C(O)NR^{4a}R^{4a}$, $(CR'R')_tS(O)_pR^{4b}$, $(CR'R')_tS(O)_2NR^{4a}R^{4a}$, $(CR'R')_tNR^{4f}S(O)_2R^{4b}$, $(CR'R')_tNR^{4f}S(O)_2NR^{4a}R^{4a}$, C_{1-6} haloalkyl, and $(CR'R')_t$ phenyl substituted with 0-3 R^{4e} .

alternatively, two R^4 on adjacent atoms join to form $-O-(CH_2)-O-$;

R^{4a}, at each occurrence, is independently selected from H, methyl, ethyl, propyl, i-propyl, butyl, s-butyl, i-butyl, t-butyl, pentyl, hexyl, allyl, propargyl, and a (CH₂)₁₋₃₋₆ carbocyclic residue selected from cyclopropyl, cyclobutyl, cyclopentyl and cyclohexyl;

R^{4b}, at each occurrence, is selected from methyl, ethyl, propyl, i-propyl, butyl, s-butyl, i-butyl, t-butyl, pentyl, hexyl, allyl, propargyl, a (CH₂)₁₋₃₋₆ carbocyclic residue substituted with 0-3 R^{4c}, wherein the carbocyclic residue is selected from cyclopropyl, cyclobutyl, cyclopentyl and cyclohexyl, and a (CH₂)₁₋₅₋₆ membered heterocyclic system containing 1-4 heteroatoms selected from N, O, and S, substituted with 0-2 R^{4c}, wherein the heterocyclic system is selected from pyridinyl, thiophenyl, furanyl, indazolyl, benzothiazolyl, benzimidazolyl, benzothiophenyl, benzofuranyl, benzoxazolyl, benzisoxazolyl, quinolinyl, isoquinolinyl, imidazolyl, indolyl, indolinyl, isoindolyl, isothiadiazolyl, isoxazolyl, piperidinyl, pyrazolyl, 1,2,4-triazolyl, 1,2,3-triazolyl, tetrazolyl, thiadiazolyl, thiazolyl, oxazolyl, pyrazinyl, and pyrimidinyl;


R^{4d}, at each occurrence, is selected from H, methyl, CF₃, ethyl, propyl, i-propyl, butyl, s-butyl, i-butyl, t-butyl, pentyl, hexyl, allyl, propargyl, and a (CH₂)₁₋₃₋₆ carbocyclic residue selected from cyclopropyl, cyclobutyl, cyclopentyl and cyclohexyl;

R^{4e}, at each occurrence, is selected from C₁₋₆ alkyl, C₂₋₈ alkenyl, C₂₋₈ alkynyl, (CH₂)₁₋₃₋₆ cycloalkyl, Cl, F, Br, I, CN, NO₂, (CF₂)₁CF₃, (CH₂)₁OC₁₋₅ alkyl, OH, SH, (CH₂)₁SC₁₋₅ alkyl, (CH₂)₁NR^{4f}R^{4f}, and (CH₂)₁phenyl;

R^{4f}, at each occurrence, is selected from H, methyl, ethyl, propyl, i-propyl, butyl, and cyclopropyl, cyclobutyl, and phenyl;

R⁵, at each occurrence, is selected from methyl, ethyl, propyl, i-propyl, butyl, i-butyl, s-butyl, t-butyl, pentyl, hexyl, (CR'R')₁₋₃₋₆ cycloalkyl, Cl, Br, I, F, NO₂, CN, (CR'R')₁NR^{5a}R^{5a},

$(\text{CR}'\text{R}')_f\text{OH}$, $(\text{CR}'\text{R}')_f\text{OR}^{5d}$, $(\text{CR}'\text{R}')_f\text{SH}$, $(\text{CR}'\text{R}')_f\text{C(O)H}$, $(\text{CR}'\text{R}')_f\text{SR}^{5d}$,
 $(\text{CR}'\text{R}')_f\text{C(O)OH}$, $(\text{CR}'\text{R}')_f\text{C(O)R}^{5b}$, $(\text{CR}'\text{R}')_f\text{C(O)NR}^{5a}\text{R}^{5a}$, $(\text{CR}'\text{R}')_f\text{NR}^{5f}\text{C(O)R}^{5b}$,
 $(\text{CR}'\text{R}')_f\text{C(O)OR}^{5d}$, $(\text{CR}'\text{R}')_f\text{OC(O)R}^{5b}$, $(\text{CR}'\text{R}')_f\text{NR}^{5f}\text{C(O)OR}^{5d}$,
 $(\text{CR}'\text{R}')_f\text{OC(O)NR}^{5a}\text{R}^{5a}$, $(\text{CR}'\text{R}')_f\text{NR}^{5a}\text{C(O)NR}^{5a}\text{R}^{5a}$, $(\text{CR}'\text{R}')_f\text{NR}^{7a}\text{C(O)NR}^{7a}\text{R}^{7a}$,
 $(\text{CR}'\text{R}')_f\text{NR}^{7a}\text{C(O)O}(\text{CR}'\text{R}')_f\text{R}^{7d}$, $(\text{CR}'\text{R}')_f\text{S(O)}_p\text{R}^{5b}$, $(\text{CR}'\text{R}')_f\text{S(O)}_2\text{NR}^{5a}\text{R}^{5a}$,
 $(\text{CR}'\text{R}')_f\text{NR}^{5f}\text{S(O)}_2\text{R}^{5b}$, C_{1-6} haloalkyl, and $(\text{CHR}')_f$ phenyl substituted with 0-3 R^{5c} , a
 $(\text{CRR})_f$ -5-10 membered heterocyclic system containing 1-4 heteroatoms selected from N, O,
 and S, substituted with 0-2 R^{5c}



alternatively, two R^5 on adjacent atoms join to form $-\text{O}-(\text{CH}_2)-\text{O}-$;

R^{5a} , at each occurrence, is independently selected from H, methyl, ethyl, propyl, i-propyl, butyl, s-butyl, i-butyl, t-butyl, pentyl, hexyl, allyl, propargyl, and a $(\text{CH}_2)_f\text{-C}_{3-10}$ carbocyclic residue substituted with 0-1 R^{5c} , wherein the carbocyclic residue is selected from cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, phenyl and naphthyl;

R^{5b} , at each occurrence, is selected from methyl, ethyl, propyl, i-propyl, butyl, s-butyl, i-butyl, t-butyl, pentyl, hexyl, allyl, propargyl, a $(\text{CH}_2)_f\text{-C}_{3-6}$ carbocyclic residue selected from

cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, and phenyl; and a $(CH_2)_{2-5-6}$ membered heterocyclic system containing 1-4 heteroatoms selected from N, O, and S, wherein the heterocyclic system is selected from pyridinyl, thiophenyl, furanyl, indazolyl, azetidiny, benzothiazolyl, benzimidazolyl, benzothiophenyl, benzofuranyl, benzoxazolyl, benzisoxazolyl, quinolinyl, isoquinolinyl, imidazolyl, indolyl, indolinyl, isoindolyl, isothiadiazolyl, isoxazolyl, morphinyl, piperidinyl, pyrrolyl, 2,5-dihydropyrrolyl, pyrrazolyl, 1,2,4-triazolyl, 1,2,3-triazolyl, tetrazolyl, thiadiazolyl, thiazolyl, oxazolyl, pyrazinyl, and pyrimidinyl;

R^{5d}, at each occurrence, is selected from H, methyl, CF₃, ethyl, propyl, i-propyl, butyl, s-butyl, i-butyl, t-butyl, pentyl, hexyl, allyl, propargyl, and a $(CH_2)_1-C_{3-6}$ carbocyclic residue selected from cyclopropyl, cyclobutyl, cyclopentyl and cyclohexyl;

R^{5e}, at each occurrence, is selected from C₁₋₆ alkyl, C₂₋₈ alkenyl, C₂₋₈ alkynyl, $(CH_2)_1-C_{3-6}$ cycloalkyl, Cl, F, Br, I, CN, NO₂, $(CF_2)_1CF_3$, $(CH_2)_1OC_{1-5}$ alkyl, OH, SH, $(CH_2)_1SC_{1-5}$ alkyl, $(CH_2)_1NR^{4f}R^{4f}$, and $(CH_2)_1$ phenyl; and

R^{5f}, at each occurrence, is selected from H, methyl, ethyl, propyl, i-propyl, butyl, and cyclopropyl, cyclobutyl, and phenyl.

R⁴, at each occurrence, is selected from C₁₋₈ alkyl, C₂₋₈ alkenyl, C₂₋₈ alkynyl, $(CH_2)_1-C_{3-6}$ cycloalkyl, Cl, Br, I, F, NO₂, CN, $(CR'R'')_fNR^{4a}R^{4a}$, $(CR'R'')_fOH$, $(CR'R'')_fO(CR'R'')_fR^{4d}$, $(CR'R'')_fSH$, $(CR'R'')_fC(O)H$, $(CR'R'')_fS(CR'R'')_fR^{4d}$, $(CR'R'')_fC(O)OH$, $(CR'R'')_fC(O)(CR'R'')_fR^{4b}$, $(CR'R'')_fC(O)NR^{4a}R^{4a}$, $(CR'R'')_fNR^{4f}C(O)(CR'R'')_fR^{4b}$, $(CR'R'')_fC(O)O(CR'R'')_fR^{4d}$, $(CR'R'')_fOC(O)(CR'R'')_fR^{4b}$, $(CR'R'')_fNR^{4f}C(O)O(CR'R'')_fR^{4d}$, $(CR'R'')_fOC(O)NR^{4a}R^{4a}$, $(CR'R'')_fNR^{4a}C(S)NR^{4a}(CR'R'')_fR^{4d}$, $(CR'R'')_fNR^{4a}C(O)NR^{4a}R^{4a}$, $(CR'R'')_fC(=NR^{4f})NR^{4a}R^{4a}$, $(CR'R'')_fNHC(=NR^{4f})NR^{4f}R^{4f}$, $(CR'R'')_fS(O)_p(CR'R'')_fR^{4b}$, $(CR'R'')_fS(O)_2NR^{4a}R^{4a}$, $(CR'R'')_fNR^{4f}S(O)_2NR^{4a}R^{4a}$, $(CR'R'')_fNR^{4f}S(O)_2(CR'R'')_fR^{4b}$,

C_{1-6} -haloalkyl, C_{2-8} -alkenyl substituted with 0-3 R^2 , C_{2-8} -alkynyl substituted with 0-3 R^2 , and $(CR^2R^3)_f$ -phenyl substituted with 0-3 R^{4e} ;

alternatively, two R^4 on adjacent atoms on R^1 may join to form a cyclic acetal;

R^{4a} , at each occurrence, is independently selected from H, methyl substituted with 0-1 R^{4e} , C_{2-6} -alkyl substituted with 0-2 R^{4e} , C_{3-8} -alkenyl substituted with 0-2 R^{4e} , C_{3-8} -alkynyl substituted with 0-2 R^{4e} , a $(CH_2)_f$ - C_{3-10} -carbocyclic residue substituted with 0-5 R^{4e} , and a $(CH_2)_f$ -5-10 membered heterocyclic system containing 1-4 heteroatoms selected from N, O, and S, substituted with 0-2 R^{4e} ;

R^{4b} , at each occurrence, is selected from C_{1-6} -alkyl substituted with 0-2 R^{4e} , C_{2-8} -alkenyl substituted with 0-2 R^{4e} , C_{3-8} -alkynyl substituted with 0-2 R^{4e} , a $(CH_2)_f$ - C_{3-6} -carbocyclic residue substituted with 0-3 R^{4e} , and a $(CH_2)_f$ -5-6 membered heterocyclic system containing 1-4 heteroatoms selected from N, O, and S, substituted with 0-2 R^{4e} ;

R^{4d} , at each occurrence, is selected from C_{2-8} -alkenyl substituted with 0-2 R^{4e} , C_{3-8} -alkynyl substituted with 0-2 R^{4e} , methyl, CF_3 , C_{2-6} -alkyl substituted with 0-3 R^{4e} , a $(CH_2)_f$ - C_{3-10} -carbocyclic residue substituted with 0-3 R^{4e} , and a $(CH_2)_f$ -5-6 membered heterocyclic system containing 1-4 heteroatoms selected from N, O, and S, substituted with 0-3 R^{4e} ;

R^{4e} , at each occurrence, is selected from C_{1-6} -alkyl, C_{2-8} -alkenyl, C_{2-8} -alkynyl, $(CH_2)_f$ - C_{3-6} -cycloalkyl, Cl, F, Br, I, CN, NO_2 , $(CF_2)_f$ - CF_3 , $(CH_2)_f$ - OC_{1-5} -alkyl, OH, SH, $(CH_2)_f$ - SC_{1-5} -alkyl, $(CH_2)_f$ - $NR^{4f}R^{4f}$, and $(CH_2)_f$ -phenyl;

R^{4f} , at each occurrence, is selected from H, C_{1-5} -alkyl, and C_{3-6} -cycloalkyl, and phenyl;

R^{4g} is independently selected from $-C(O)R^{4b}$, $-C(O)OR^{4d}$, $-C(O)NR^{4f}R^{4f'}$, and $-(CH_2)_f$ phenyl;

R^{5i} , at each occurrence, is selected from C_{1-6} alkyl, C_{2-6} alkenyl, C_{2-6} alkynyl, $(CH_2)_f C_{3-6}$ cycloalkyl, Cl, Br, I, F, NO_2 , CN, $(CR'R'')_f NR^{5a}R^{5a}$, $(CR'R'')_f OH$, $(CR'R'')_f O(CR'R'')_f R^{5d}$, $(CR'R'')_f SH$, $(CR'R'')_f C(O)H$, $(CR'R'')_f S(CR'R'')_f R^{5d}$, $(CR'R'')_f C(O)OH$, $(CR'R'')_f C(O)(CR'R'')_f R^{5b}$, $(CR'R'')_f C(O)NR^{5a}R^{5a}$, $(CR'R'')_f NR^{5f}C(O)(CR'R'')_f R^{5b}$, $(CR'R'')_f C(O)O(CR'R'')_f R^{5d}$, $(CR'R'')_f OC(O)(CR'R'')_f R^{5b}$, $(CR'R'')_f NR^{5f}C(O)O(CR'R'')_f R^{5d}$, $(CR'R'')_f OC(O)NR^{5a}R^{5a}$, $(CR'R'')_f NR^{5a}C(O)NR^{5a}R^{5a}$, $(CR'R'')_f C(=NR^{5f})NR^{5a}R^{5a}$, $(CR'R'')_f NHC(=NR^{5f})NR^{5f}R^{5f}$, $(CR'R'')_f S(O)_p(CR'R'')_f R^{5b}$, $(CR'R'')_f S(O)_2 NR^{5a}R^{5a}$, $(CR'R'')_f NR^{5a}S(O)_2 NR^{5a}R^{5a}$, $(CR'R'')_f NR^{5f}S(O)_2(CR'R'')_f R^{5b}$, C_{1-6} haloalkyl, C_{2-6} alkenyl substituted with $0-3 R^2$, C_{2-6} alkynyl substituted with $0-3 R^2$, $(CR'R'')_f$ phenyl substituted with $0-3 R^{5e}$, and a $(CRR')_5-10$ membered heterocyclic system containing 1-4 heteroatoms selected from N, O, and S, substituted with $0-2 R^{5e}$;

alternatively, two R^{5i} on adjacent atoms on R^2 may join to form a cyclic acetal;

R^{5a} , at each occurrence, is independently selected from H, methyl-substituted with $0-1 R^{5e}$, C_{2-6} alkyl-substituted with $0-2 R^{5e}$, C_{3-6} alkenyl-substituted with $0-2 R^{5e}$, C_{3-6} alkynyl substituted with $0-2 R^{5e}$, a $(CH_2)_f C_{3-10}$ carbocyclic residue substituted with $0-5 R^{5e}$, and a $(CH_2)_f$ 5-10 membered heterocyclic system containing 1-4 heteroatoms selected from N, O, and S, substituted with $0-2 R^{5e}$;

R^{5b} , at each occurrence, is independently selected from C_{1-6} alkyl-substituted with $0-2 R^{5e}$, C_{3-6} alkenyl-substituted with $0-2 R^{5e}$, C_{3-6} alkynyl-substituted with $0-2 R^{5e}$, a $(CH_2)_f C_{3-6}$

carboeyelic residue substituted with 0-3 R^{5e}, and a (CH₂)_f-5-6 membered heterocyclic system containing 1-4 heteroatoms selected from N, O, and S, substituted with 0-2 R^{5e};

R^{5d}, at each occurrence, is independently selected from C₃₋₈ alkenyl substituted with 0-2 R^{5e}, C₃₋₈ alkynyl substituted with 0-2 R^{5e}, methyl, CF₃, C₂₋₆ alkyl substituted with 0-3 R^{5e}, a (CH₂)_f-C₃₋₁₀ carboeyelic residue substituted with 0-3 R^{5e}, and a (CH₂)_f-5-6 membered heterocyclic system containing 1-4 heteroatoms selected from N, O, and S, substituted with 0-3 R^{5e};

R^{5e}, at each occurrence, is selected from C₁₋₆ alkyl, C₂₋₈ alkenyl, C₂₋₈ alkynyl, (CH₂)_f-C₃₋₆ cycloalkyl, Cl, F, Br, I, CN, NO₂, (CF₂)_fCF₃, (CH₂)₄OC₁₋₅ alkyl, OH, SH, (CH₂)_fSC₁₋₅ alkyl, (CH₂)_fNR^{5f}R^{5f}, and (CH₂)_fphenyl;

R^{5f}, at each occurrence, is selected from H, C₁₋₅ alkyl, and C₃₋₆ cycloalkyl, and phenyl;

R^{5g} is independently selected from C(O)R^{5b}, C(O)OR^{5d}, C(O)NR^{5f}R^{5f}, and (CH₂)_fphenyl;

R', at each occurrence, is selected from H, C₁₋₆ alkyl, C₂₋₈ alkenyl, C₂₋₈ alkynyl, (CH₂)_f-C₃₋₆ cycloalkyl, and (CH₂)_fphenyl substituted with R^{5c};

R⁶, is selected from H, C₁₋₆ alkyl, C₂₋₆ alkenyl, C₂₋₆ alkynyl, (CRR)_qOH, (CRR)_qSH, (CRR)_qOR^{6d}, (CRR)_qS(O)_pR^{6d}, (CRR)_tC(O)R^{6b}, (CRR)_tNR^{6a}R^{6a}, (CRR)_tC(O)NR^{6a}R^{6a}, (CRR)_tC(O)NR^{6a}OR^{6d}, (CRR)SO₂NR^{6a}R^{6a}, (CRR)_tC(O)OR^{6d}, a (CRR)_t-C₃₋₁₀ carbocyclic residue substituted with 0-5 R^{6e}, and a (CRR)_t-5-10 membered heterocyclic system containing 1-4 heteroatoms selected from N, O, and S, substituted with 0-3 R^{6e};

alternatively, R⁶ and R⁷ join to form a C₃₋₆ cycloalkyl substituted with 0-2 R^{6g}, a 5-6 membered ring lactam substituted with 0-2 R^{6g}, or a 5-6 membered ring lactone substituted with 0-2 R^{6g};

R^{6a}, at each occurrence, is independently selected from H, methyl, C₂₋₆ alkyl substituted with 0-3 R^{6c}, C₃₋₈ alkenyl substituted with 0-3 R^{6c}, C₃₋₈ alkynyl substituted with 0-3 R^{6c}, (CH₂)_rC₃₋₆ cycloalkyl, a (CH₂)_rC₃₋₁₀ carbocyclic residue substituted with 0-5 R^{6c}, and a (CH₂)_r-5-10 membered heterocyclic system containing 1-4 heteroatoms selected from N, O, and S, substituted with 0-3 R^{6c};

R^{6b}, at each occurrence, is independently selected from C₁₋₆ alkyl substituted with 0-3 R^{6c}, C₂₋₈ alkenyl substituted with 0-3 R^{6c}, C₂₋₈ alkynyl substituted with 0-3 R^{6c}, a (CH₂)_rC₃₋₆ carbocyclic residue substituted with 0-2 R^{6c}, and a (CH₂)_r-5-6 membered heterocyclic system containing 1-4 heteroatoms selected from N, O, and S, substituted with 0-3 R^{6c};

R^{6d}, at each occurrence, is independently selected from H, methyl, -CF₃, C₂₋₆ alkyl substituted with 0-3 R^{6c}, C₃₋₆ alkenyl substituted with 0-3 R^{6c}, C₃₋₆ alkynyl substituted with 0-3 R^{6c}, a C₃₋₁₀ carbocyclic residue substituted with 0-3 R^{6c}, and a (CH₂)_r-5-6 membered heterocyclic system containing 1-4 heteroatoms selected from N, O, and S, substituted with 0-3 R^{6c};

R^{6e}, at each occurrence, is independently selected from C₁₋₆ alkyl, C₂₋₈ alkenyl, C₂₋₈ alkynyl, C₃₋₆ cycloalkyl, Cl, F, Br, I, CN, NO₂, (CF₂)_rCF₃, (CH₂)_rOC₁₋₅ alkyl, OH, -O-C₁₋₆ alkyl, SH, (CH₂)_rSC₁₋₅ alkyl, (CH₂)_rNR^{6f}R^{6f}, and (CH₂)_rphenyl;

R^{6f}, at each occurrence, is independently selected from H, C₁₋₆ alkyl, and C₃₋₆ cycloalkyl;

R^{6g} is selected from (CHR)_qOH, (CHR)_qSH, (CHR)_qOR^{7d}, (CHR)_qS(O)_pR^{6d}, (CHR)_rC(O)R^{6b}, (CHR)_qNR^{6a}R^{6a}, (CHR)_rC(O)NR^{6a}R^{6a}, (CHR)_rC(O)NR^{6a}OR^{6d}, (CHR)_qSO₂NR^{6a}R^{6a}, (CHR)_rC(O)OR^{6d}, and a (CHR)_rC₃₋₁₀ carbocyclic residue substituted with 0-5 R^{6c};

R⁷, is selected from H, C₁₋₆ alkyl, C₂₋₆ alkenyl, C₂₋₆ alkynyl, (CRR)_qOH, (CRR)_qSH, (CRR)_qOR^{7d}, (CRR)_qS(O)_pR^{7d}, (CRR)_rC(O)R^{7b}, (CRR)_rNR^{7a}R^{7a}, (CRR)_rC(O)NR^{7a}R^{7a}, (CRR)_rC(O)NR^{7a}OR^{7d}, (CRR)_qSO₂NR^{7a}R^{7a}, (CRR)_rC(O)OR^{7d},

a (CRR)_r-C₃₋₁₀ carbocyclic residue substituted with 0-5 R^{7c}, and a (CRR)_r-5-10 membered heterocyclic system containing 1-4 heteroatoms selected from N, O, and S, substituted with 0-3 R^{7c};

R^{7a}, at each occurrence, is independently selected from H, methyl, C₂₋₆ alkyl substituted with 0-3 R^{7c}, C₃₋₈ alkenyl substituted with 0-3 R^{7c}, C₃₋₈ alkynyl substituted with 0-3 R^{7c}, (CH₂)_r-C₃₋₆ cycloalkyl, a (CH₂)_r-C₃₋₁₀ carbocyclic residue substituted with 0-5 R^{7c}, and a (CH₂)_r-5-10 membered heterocyclic system containing 1-4 heteroatoms selected from N, O, and S, substituted with 0-3 R^{7c};

R^{7b}, at each occurrence, is independently selected from C₁₋₆ alkyl substituted with 0-3 R^{7c}, C₂₋₈ alkenyl substituted with 0-3 R^{7c}, C₂₋₈ alkynyl substituted with 0-3 R^{7c}, a (CH₂)_r-C₃₋₆ carbocyclic residue substituted with 0-2 R^{7c}, and a (CH₂)_r-5-6 membered heterocyclic system containing 1-4 heteroatoms selected from N, O, and S, substituted with 0-3 R^{7c};

R^{7d}, at each occurrence, is independently selected from H, methyl, -CF₃, C₂₋₆ alkyl substituted with 0-3 R^{7c}, C₃₋₆ alkenyl substituted with 0-3 R^{7c}, C₃₋₆ alkynyl substituted with 0-3 R^{7c}, a C₃₋₁₀ carbocyclic residue substituted with 0-3 R^{7c}, and a (CH₂)_r-5-6 membered heterocyclic system containing 1-4 heteroatoms selected from N, O, and S, substituted with 0-3 R^{7c};

R^{7e}, at each occurrence, is independently selected from C₁₋₆ alkyl, C₂₋₈ alkenyl, C₂₋₈ alkynyl, C₃₋₆ cycloalkyl, Cl, F, Br, I, CN, NO₂, (CF₂)_rCF₃, (CH₂)_rOC₁₋₅ alkyl, OH, -O-C₁₋₆ alkyl, SH, (CH₂)_rSC₁₋₅ alkyl, (CH₂)_rNR^{7f}R^{7f}, and (CH₂)_rphenyl;

R^{7f}, at each occurrence, is independently selected from H, C₁₋₆ alkyl, and C₃₋₆ cycloalkyl;

R⁸ is selected from H, C₁₋₆ alkyl, C₂₋₆ alkenyl, C₂₋₆ alkynyl, (CRR)_rOH, (CRR)_rSH, (CRR)_rOR^{8d}, (CRR)_rS(O)_pR^{8d}, (CRR)_rC(O)R^{8b}, (CRR)_rNR^{8a}R^{8a}, (CRR)_rC(O)NR^{8a}R^{8a}, (CRR)_rC(O)NR^{8a}OR^{8d}, (CRR)_rSO₂NR^{8a}R^{8a}, (CRR)_rC(O)OR^{8d}, a (CRR)_r-C₃₋₁₀ carbocyclic residue substituted with 0-5 R^{8c}, and a (CRR)_r-5-10 membered heterocyclic system containing 1-4 heteroatoms selected from N, O, and S, substituted with 0-3 R^{8c};

alternatively, R⁸ and R⁹ join to form a C₃₋₆ cycloalkyl substituted with 0-2 R^{8g}, a 5-6 membered ring lactam substituted with 0-2 R^{8g}, or a 5-6 membered ring lactone substituted with 0-2 R^{8g};

R^{8a}, at each occurrence, is independently selected from H, methyl, C₂₋₆ alkyl substituted with 0-3 R^{8c}, C₃₋₈ alkenyl substituted with 0-3 R^{8c}, C₃₋₈ alkynyl substituted with 0-3 R^{8c}, (CH₂)_rC₃₋₆ cycloalkyl, a (CH₂)_rC₃₋₁₀ carbocyclic residue substituted with 0-5 R^{8c}, and a (CH₂)_r-5-10 membered heterocyclic system containing 1-4 heteroatoms selected from N, O, and S, substituted with 0-3 R^{8c};

R^{8b}, at each occurrence, is independently selected from C₁₋₆ alkyl substituted with 0-3 R^{8c}, C₂₋₈ alkenyl substituted with 0-3 R^{8c}, C₂₋₈ alkynyl substituted with 0-3 R^{8c}, a (CH₂)_rC₃₋₆ carbocyclic residue substituted with 0-2 R^{8c}, and a (CH₂)_r-5-6 membered heterocyclic system containing 1-4 heteroatoms selected from N, O, and S, substituted with 0-3 R^{8c};

R^{8d}, at each occurrence, is independently selected from H, methyl, -CF₃, C₂₋₆ alkyl substituted with 0-3 R^{8e}, C₃₋₆ alkenyl substituted with 0-3 R^{8e}, C₃₋₆ alkynyl substituted with 0-3 R^{8e}, a C₃₋₁₀ carbocyclic residue substituted with 0-3 R^{8e}, and a (CH₂)_r-5-6 membered heterocyclic system containing 1-4 heteroatoms selected from N, O, and S, substituted with 0-3 R^{8e};

R^{8e}, at each occurrence, is independently selected from C₁₋₆ alkyl, C₂₋₈ alkenyl, C₂₋₈ alkynyl, C₃₋₆ cycloalkyl, Cl, F, Br, I, CN, NO₂, (CF₂)_rCF₃, (CH₂)_rOC₁₋₅ alkyl, OH, -O-C₁₋₆ alkyl, SH, (CH₂)_rSC₁₋₅ alkyl, (CH₂)_rNR^{8f}R^{8f}, and (CH₂)_rphenyl;

R^{8f}, at each occurrence, is independently selected from H, C₁₋₆ alkyl, and C₃₋₆ cycloalkyl;

R^{8g} is selected from (CHR)_qOH, (CHR)_qSH, (CHR)_qOR^{8d}, (CHR)_qS(O)_pR^{8d}, (CHR)_rC(O)R^{8b}, (CHR)_qNR^{8a}R^{8a}, (CHR)_rC(O)NR^{8a}R^{8a}, (CHR)_rC(O)NR^{8a}OR^{8d}, (CHR)_qSO₂NR^{8a}R^{8a}, (CHR)_rC(O)OR^{8d}, and a (CHR)_r-C₃₋₁₀ carbocyclic residue substituted with 0-5 R^{8c};

R⁹ is selected from H, C₁₋₆ alkyl, C₂₋₆ alkenyl, C₂₋₆ alkynyl, (CRR)_rOH, (CRR)_rSH, (CRR)_rOR^{9d}, (CRR)_rS(O)_pR^{9d}, (CRR)_rC(O)R^{9b}, (CRR)_rNR^{9a}R^{9a}, (CRR)_rC(O)NR^{9a}R^{9a}, (CRR)_rC(O)NR^{9a}OR^{9d}, (CRR)_rSO₂NR^{9a}R^{9a}, (CRR)_rC(O)OR^{9d}, a (CRR)_r-C₃₋₁₀

carbocyclic residue substituted with 0-5 R^{9c}, and a (CRR)_r-5-10 membered heterocyclic system containing 1-4 heteroatoms selected from N, O, and S, substituted with 0-3 R^{9c};

R^{9a}, at each occurrence, is independently selected from H, methyl, C₂₋₆ alkyl substituted with 0-3 R^{9c}, C₃₋₈ alkenyl substituted with 0-3 R^{9c}, C₃₋₈ alkynyl substituted with 0-3 R^{9c}, (CH₂)_rC₃₋₆ cycloalkyl, a (CH₂)_r-C₃₋₁₀ carbocyclic residue substituted with 0-5 R^{9c}, and a (CH₂)_r-5-10 membered heterocyclic system containing 1-4 heteroatoms selected from N, O, and S, substituted with 0-3 R^{9c};

R^{9b}, at each occurrence, is independently selected from C₁₋₆ alkyl substituted with 0-3 R^{9c}, C₂₋₈ alkenyl substituted with 0-3 R^{9c}, C₂₋₈ alkynyl substituted with 0-3 R^{9c}, a (CH₂)_r-C₃₋₆ carbocyclic residue substituted with 0-2 R^{9c}, and a (CH₂)_r-5-6 membered heterocyclic system containing 1-4 heteroatoms selected from N, O, and S, substituted with 0-3 R^{9c};

R^{9d}, at each occurrence, is independently selected from H, methyl, -CF₃, C₂₋₆ alkyl substituted with 0-3 R^{9c}, C₃₋₆ alkenyl substituted with 0-3 R^{9c}, C₃₋₆ alkynyl substituted with 0-3 R^{9c}, a C₃₋₁₀ carbocyclic residue substituted with 0-3 R^{9c}, and a (CH₂)_r-5-6 membered heterocyclic system containing 1-4 heteroatoms selected from N, O, and S, substituted with 0-3 R^{9c};

R^{9e}, at each occurrence, is independently selected from C₁₋₆ alkyl, C₂₋₈ alkenyl, C₂₋₈ alkynyl, C₃₋₆ cycloalkyl, Cl, F, Br, I, CN, NO₂, (CF₂)_rCF₃, (CH₂)_rOC₁₋₅ alkyl, OH, -O-C₁₋₆ alkyl, SH, (CH₂)_rSC₁₋₅ alkyl, (CH₂)_rNR^{9f}R^{9f}, and (CH₂)_rphenyl;

R^{9f}, at each occurrence, is independently selected from H, C₁₋₆ alkyl, and C₃₋₆ cycloalkyl;

R¹⁰ is selected from H, C₁₋₆ alkyl, C₂₋₆ alkenyl, C₂₋₆ alkynyl, (CRR)_rOH, (CRR)_rSH, (CRR)_rOR^{10d}, (CRR)_rS(O)_pR^{10d}, (CRR)_rC(O)R^{10b}, (CRR)_rNR^{10a}R^{10a}, (CRR)_rC(O)NR^{10a}R^{10a}, (CRR)_rC(O)NR^{10a}OR^{10d}, (CRR)_rSO₂NR^{10a}R^{10a}, (CRR)_rC(O)OR^{10d}, a (CRR)_r-C₃₋₁₀ carbocyclic residue substituted with 0-5 R^{10e}, and a (CRR)_r-5-10 membered heterocyclic system containing 1-4 heteroatoms selected from N, O, and S, substituted with 0-3 R^{10e};

alternatively, R¹⁰ and R¹¹ join to form a C₃₋₆ cycloalkyl substituted with 0-2 R^{10g}, a 5-6

membered ring lactam substituted with 0-2 R^{10g}, or a 5-6 membered ring lactone substituted with 0-2 R^{10g};

R^{10a}, at each occurrence, is independently selected from H, methyl, C₂₋₆ alkyl substituted with 0-3 R^{10e}, C₃₋₈ alkenyl substituted with 0-3 R^{10e}, C₃₋₈ alkynyl substituted with 0-3 R^{10e}, (CH₂)_rC₃₋₆ cycloalkyl, a (CH₂)_rC₃₋₁₀ carbocyclic residue substituted with 0-5 R^{10e}, and a (CH₂)_r-5-10 membered heterocyclic system containing 1-4 heteroatoms selected from N, O, and S, substituted with 0-3 R^{10e};

R^{10b}, at each occurrence, is independently selected from C₁₋₆ alkyl substituted with 0-3 R^{10e}, C₂₋₈ alkenyl substituted with 0-3 R^{10e}, C₂₋₈ alkynyl substituted with 0-3 R^{10e}, a (CH₂)_rC₃₋₆ carbocyclic residue substituted with 0-2 R^{10e}, and a (CH₂)_r-5-6 membered heterocyclic system containing 1-4 heteroatoms selected from N, O, and S, substituted with 0-3 R^{10e};

R^{10d}, at each occurrence, is independently selected from H, methyl, -CF₃, C₂₋₆ alkyl substituted with 0-3 R^{10e}, C₃₋₆ alkenyl substituted with 0-3 R^{10e}, C₃₋₆ alkynyl substituted with 0-3 R^{10e}, a C₃₋₁₀ carbocyclic residue substituted with 0-3 R^{10e}, and a (CH₂)_r-5-6 membered heterocyclic system containing 1-4 heteroatoms selected from N, O, and S, substituted with 0-3 R^{10e};

R^{10e}, at each occurrence, is independently selected from C₁₋₆ alkyl, C₂₋₈ alkenyl, C₂₋₈ alkynyl, C₃₋₆ cycloalkyl, Cl, F, Br, I, CN, NO₂, (CF₂)_rCF₃, (CH₂)_rOC₁₋₅ alkyl, OH, -O-C₁₋₆ alkyl, SH, (CH₂)_rSC₁₋₅ alkyl, (CH₂)_rNR^{10f}R^{10f}, and (CH₂)_rphenyl;

R^{10f}, at each occurrence, is independently selected from H, C₁₋₆ alkyl, and C₃₋₆ cycloalkyl;

R^{10g} is selected from (CHR)_qOH, (CHR)_qSH, (CHR)_qOR^{10d}, (CHR)_qS(O)_pR^{10d},

(CHR)_rC(O)R^{10b}, (CHR)_qNR^{10a}R^{10a}, (CHR)_rC(O)NR^{10a}R^{10a},

(CHR)_rC(O)NR^{10a}OR^{10d}, (CHR)_qSO₂NR^{10a}R^{10a}, (CHR)_rC(O)OR^{10d}, and a (CHR)_r-

C₃₋₁₀ carbocyclic residue substituted with 0-5 R^{10e};

R^{11} , is selected from H, C_{1-6} alkyl, C_{2-6} alkenyl, C_{2-6} alkynyl, $(CRR)_rOH$, $(CRR)_rSH$, $(CRR)_rOR^{11d}$, $(CRR)_rS(O)_pR^{11d}$, $(CRR)_rC(O)R^{11b}$, $(CRR)_rNR^{11a}R^{11a}$, $(CRR)_rC(O)NR^{11a}R^{11a}$, $(CRR)_rC(O)NR^{11a}OR^{11d}$, $(CRR)_rSO_2NR^{11a}R^{11a}$, $(CRR)_rC(O)OR^{11d}$, a $(CRR)_rC_{3-10}$ carbocyclic residue substituted with 0-5 R^{11e} , and a $(CRR)_r$ -5-10 membered heterocyclic system containing 1-4 heteroatoms selected from N, O, and S, substituted with 0-3 R^{11e} ;

R^{11a} , at each occurrence, is independently selected from H, methyl, C_{2-6} alkyl substituted with 0-3 R^{11e} , C_{3-8} alkenyl substituted with 0-3 R^{11e} , C_{3-8} alkynyl substituted with 0-3 R^{11e} , $(CH_2)_rC_{3-6}$ cycloalkyl, a $(CH_2)_rC_{3-10}$ carbocyclic residue substituted with 0-5 R^{11e} , and a $(CH_2)_r$ -5-10 membered heterocyclic system containing 1-4 heteroatoms selected from N, O, and S, substituted with 0-3 R^{11e} ;

R^{11b} , at each occurrence, is independently selected from C_{1-6} alkyl substituted with 0-3 R^{11e} , C_{2-8} alkenyl substituted with 0-3 R^{11e} , C_{2-8} alkynyl substituted with 0-3 R^{11e} , a $(CH_2)_rC_{3-6}$ carbocyclic residue substituted with 0-2 R^{11e} , and a $(CH_2)_r$ -5-6 membered heterocyclic system containing 1-4 heteroatoms selected from N, O, and S, substituted with 0-3 R^{11e} ;

R^{11d} , at each occurrence, is independently selected from H, methyl, $-CF_3$, C_{2-6} alkyl substituted with 0-3 R^{11e} , C_{3-6} alkenyl substituted with 0-3 R^{11e} , C_{3-6} alkynyl substituted with 0-3 R^{11e} , a C_{3-10} carbocyclic residue substituted with 0-3 R^{11e} , and a $(CH_2)_r$ -5-6 membered heterocyclic system containing 1-4 heteroatoms selected from N, O, and S, substituted with 0-3 R^{11e} ;

R^{11e} , at each occurrence, is independently selected from C_{1-6} alkyl, C_{2-8} alkenyl, C_{2-8} alkynyl, C_{3-6} cycloalkyl, Cl, F, Br, I, CN, NO_2 , $(CF_2)_rCF_3$, $(CH_2)_rOC_{1-5}$ alkyl, OH, $-OC_{1-6}$ alkyl, SH, $(CH_2)_rSC_{1-5}$ alkyl, $(CH_2)_rNR^{11f}R^{11f}$, and $(CH_2)_r$ phenyl;

R^{11f} , at each occurrence, is independently selected from H, C_{1-6} alkyl, and C_{3-6} cycloalkyl;

R^{12} is selected from H, C_{1-6} alkyl, C_{2-6} alkenyl, C_{2-6} alkynyl, $(CRR)_qOH$, $(CRR)_qSH$, $(CRR)_qOR^{12d}$, $(CRR)_qS(O)_pR^{12d}$, $(CRR)_rC(O)R^{12b}$, $(CRR)_rNR^{12a}R^{12a}$, $(CRR)_rC(O)NR^{12a}R^{12a}$, $(CRR)_rC(O)NR^{12a}OR^{12d}$, $(CRR)_qSO_2NR^{12a}R^{12a}$,

(CRR)_rC(O)OR^{12d}, a (CRR)_rC₃₋₁₀ carbocyclic residue substituted with 0-5 R^{12c}, and a (CRR)_r-5-10 membered heterocyclic system containing 1-4 heteroatoms selected from N, O, and S, substituted with 0-3 R^{12c};

R^{12a}, at each occurrence, is independently selected from H, methyl, C₂₋₆ alkyl substituted with 0-3 R^{12c}, C₃₋₈ alkenyl substituted with 0-3 R^{12c}, C₃₋₈ alkynyl substituted with 0-3 R^{12c}, (CH₂)_rC₃₋₆ cycloalkyl, a (CH₂)_rC₃₋₁₀ carbocyclic residue substituted with 0-5 R^{12c}, and a (CH₂)_r-5-10 membered heterocyclic system containing 1-4 heteroatoms selected from N, O, and S, substituted with 0-3 R^{12c};

R^{12b}, at each occurrence, is independently selected from C₁₋₆ alkyl substituted with 0-3 R^{12c}, C₂₋₈ alkenyl substituted with 0-3 R^{12c}, C₂₋₈ alkynyl substituted with 0-3 R^{12c}, a (CH₂)_rC₃₋₆ carbocyclic residue substituted with 0-2 R^{12c}, and a (CH₂)_r-5-6 membered heterocyclic system containing 1-4 heteroatoms selected from N, O, and S, substituted with 0-3 R^{12c};

R^{12d}, at each occurrence, is independently selected from H, methyl, -CF₃, C₂₋₆ alkyl substituted with 0-3 R^{12c}, C₃₋₆ alkenyl substituted with 0-3 R^{12c}, C₃₋₆ alkynyl substituted with 0-3 R^{12c}, a C₃₋₁₀ carbocyclic residue substituted with 0-3 R^{12c}, and a (CH₂)_r-5-6 membered heterocyclic system containing 1-4 heteroatoms selected from N, O, and S, substituted with 0-3 R^{12c};

R^{12e}, at each occurrence, is independently selected from C₁₋₆ alkyl, C₂₋₈ alkenyl, C₂₋₈ alkynyl, C₃₋₆ cycloalkyl, Cl, F, Br, I, CN, NO₂, (CF₂)_rCF₃, (CH₂)_rOC₁₋₅ alkyl, OH, -O-C₁₋₆ alkyl, SH, (CH₂)_rSC₁₋₅ alkyl, (CH₂)_rNR^{12f}R^{12f}, and (CH₂)_rphenyl;

R^{12f}, at each occurrence, is selected from H, C₁₋₆ alkyl, and C₃₋₆ cycloalkyl;

R¹³, at each occurrence, is independently selected from H, and C₁₋₄alkyl substituted with 0-1 R^{13b}, -OH, -NH₂, F, Cl, Br, I, -OR^{13a}, -N(R^{13a})₂, and C₁₋₄ alkyl substituted with 0-3 R^{13b};

R^{13b}, at each occurrence, is independently selected from -OH, -SH, -NR^{13c}R^{13c}, -C(O)NR^{13c}R^{13c}, and -NHC(O)R^{13c};

R^{13c} is selected from H, C₁₋₄ alkyl and C₃₋₆ cycloalkyl;

R¹⁴ is independently selected from H, and C₁₋₄alkyl substituted with 0-1 R^{14b};

R^{14b}, at each occurrence, is independently selected from -OH, -SH, -NR^{14c}R^{14c}, -C(O)NR^{14c}R^{14c}, and -NHC(O)R^{14c};

R^{14c} is selected from H, C₁₋₄ alkyl and C₃₋₆ cycloalkyl;

R¹⁶ is selected from H, C₁₋₄ alkyl substituted with 0-3 R^{16a}, and C₃₋₆ cycloalkyl substituted with 0-3 R^{16a};

R^{16a} is selected from C₁₋₄ alkyl, -OH, -SH, -NR^{16c}R^{16c}, -C(O)NR^{16c}R^{16c}, and -NHC(O)R^{16c};

R^{16c} is selected from H, C₁₋₄ alkyl and C₃₋₆ cycloalkyl;

R¹⁷ is selected from H, C₁₋₄ alkyl, and C₃₋₄ cycloalkyl;

R¹⁸ is selected from H, C₁₋₄ alkyl, and C₃₋₄ cycloalkyl;

~~R¹⁹ is selected from H, C₁₋₄ alkyl, C₃₋₄ cycloalkyl, C(O)H, and C(O)-C₁₋₄alkyl;~~

~~R²⁴, at each occurrence, is independently selected from H and C₁₋₄alkyl;~~

~~alternatively, two R²⁴s, along with the carbon atom to which they are attached, join to form a C₃₋₆ carbocyclic ring;~~

~~R²⁵, at each occurrence, is independently selected from H, C₁₋₄alkyl, OH, NH₂, O-C₁₋₄ alkyl, NR^{25a}R^{25a}, C(O)NR^{25a}R^{25a}, NR^{25a}C(O)R^{25b}, NR^{25a}C(O)OR^{25d}, OC(O)NR^{25a}R^{25a}, and (CHR)_xC(O)OR^{25d};~~

~~alternatively, two R^{25s}, along with the carbon atom or atoms to which they are attached, join to form a C₃₋₆ carbocyclic ring;~~

~~R^{25a}, at each occurrence, is independently selected from H, and C₁₋₄ alkyl;~~

~~R^{25b}, at each occurrence, is independently selected from H, C₁₋₄ alkyl, C₃₋₆ alkenyl, and C₃₋₆ alkynyl;~~

~~R^{25d}, at each occurrence, is independently selected from C₁₋₄ alkyl, C₃₋₆ alkenyl, and C₃₋₆ alkynyl;~~

~~R²⁶ is selected from C₁₋₄ alkyl;~~

~~n is selected from 0, 1, 2, and 3;~~

~~l is selected from 0 and 1;~~

~~m is selected from 0 and 1;~~

~~p, at each occurrence, is selected from 0, 1, or 2;~~

~~q, at each occurrence, is selected from 1, 2, 3, or 4;~~

~~r, at each occurrence, is selected from 0, 1, 2, 3, or 4;~~

~~s is selected from 0 and 1; and~~

~~t is selected from 1, 2 and 3.~~

2. (Original) The compound of claim 1, wherein:

R¹⁶ is selected from H, C₁₋₄ alkyl substituted with 0-1 R^{16a}, wherein the alkyl is selected from methyl, ethyl, propyl, i-propyl, butyl, i-butyl, and s-butyl, and C₃₋₄ cycloalkyl substituted with 0-3 R^{16a} wherein the cycloalkyl is selected from cyclopropyl and cyclobutyl;

R^{16a} is selected from methyl, ethyl, propyl, i-propyl, -OH, -SH, -NR^{16c}R^{16c}, -C(O)NR^{16c}R^{16c}, and -NHC(O)R^{16c};

R^{16c} is selected from H, methyl, ethyl, propyl, i-propyl, butyl, cyclopropyl, cyclopentyl, and cyclohexyl; and

R¹⁷ is selected from H, methyl, ethyl, propyl, and i-propyl.

3. (Original) The compound of claim 2, wherein:

R⁹ and R¹¹ are H; and

R⁸ and R¹⁰ are independently selected from H, methyl, ethyl, propyl, i-propyl, butyl, and cyclopropyl.

4. (Original) The compound of claim 3, wherein:

R³ is selected from (CRR)_qOH, (CRR)_qSH, (CRR)_qOR^{3d}, (CRR)_qS(O)_pR^{3d}, (CRR)_rC(O)R^{3b}, (CRR)_qNR^{3a}R^{3a}, (CRR)_rC(O)NR^{3a}R^{3a}, (CRR)_rC(O)NR^{3a}OR^{3d}, (CRR)_qSO₂NR^{3a}R^{3a}, (CRR)_rC(O)OR^{3d}, a (CRR)_r-C₃₋₁₀ carbocyclic residue substituted with 0-5 R^{3e}, and a (CRR)_r-5-10 membered heterocyclic system containing 1-4 heteroatoms selected from N, O, and S, substituted with 0-3 R^{3e} wherein the heterocyclic system is selected from pyridinyl, thiophenyl, furanyl, indazolyl, benzothiazolyl, benzimidazolyl, benzothiophenyl, benzofuranyl, benzoxazolyl, benzisoxazolyl, quinolinyl, isoquinolinyl, imidazolyl, indolyl, indolinyl, isoindolyl, isothiadiazolyl, isoxazolyl, piperidinyl, pyrrazolyl, pyrrolidinyl, tetrahydrofuranyl, tetrahydrothiophenyl, 1,2,4-triazolyl, 1,2,3-triazolyl, tetrazolyl, thiadiazolyl, thiazolyl, oxazolyl, pyrazinyl, and pyrimidinyl;

R^6 is selected from H, $(CRR)_qOH$, $(CRR)_qSH$, $(CRR)_qOR^{6d}$, $(CRR)_qS(O)_pR^{6d}$, $(CRR)_rC(O)R^{6b}$, $(CRR)_qNR^{6a}R^{6a}$, $(CRR)_rC(O)NR^{6a}R^{6a}$, $(CRR)_rC(O)NR^{6a}OR^{6d}$, $(CRR)_qSO_2NR^{6a}R^{6a}$, $(CRR)_rC(O)OR^{6d}$, a $(CRR)_rC_6-10$ carbocyclic residue substituted with 0-5 R^{6c} , and a $(CRR)_r5-10$ membered heterocyclic system containing 1-4 heteroatoms selected from N, O, and S, substituted with 0-6 R^{6c} wherein the heterocyclic system is selected from pyridinyl, thiophenyl, furanyl, indazolyl, benzothiazolyl, benzimidazolyl, benzothiophenyl, benzofuranyl, benzoxazolyl, benzisoxazolyl, quinolinyl, isoquinolinyl, imidazolyl, indolyl, indolinyl, isoindolyl, isothiadiazolyl, isoxazolyl, piperidinyl, pyrazolyl, pyrrolidinyl, tetrahydrofuranyl, tetrahydrothiophenyl, 1,2,4-triazolyl, 1,2,6-triazolyl, tetrazolyl, thiadiazolyl, thiazolyl, oxazolyl, pyrazinyl, and pyrimidinyl;

R^7 is H;

R^{12} is selected from H, methyl, ethyl, and propyl;

alternatively, R^3 and R^{12} join to form a C_{3-6} cycloalkyl substituted with 0-2 R^{3g} , a 5-6 membered lactam ring substituted with 0-2 R^{3g} , or a 5-6 membered lactone ring substituted with 0-2 R^{3g} ; and

$m + 1$ is equal to 1.

5. (Original) The compound of claim 4, wherein:

R^1 is selected from phenyl substituted with 0-3 R^4 and a 5-10 membered heteroaryl system substituted with 0-3 R^4 , wherein the heteroaryl is selected from benzimidazolyl, benzofuranyl, benzothiofuranyl, benzoxazolyl, benzthiazolyl, benztriazolyl, benztetrazolyl, benzisoxazolyl, benzisothiazolyl, benzimidazalonyl, cinnolinyl, furanyl, imidazolyl, indazolyl, indolyl, isoquinolinyl isothiazolyl, isoxazolyl, oxazolyl, pyrazinyl, pyrazolyl, pyridazinyl, pyridinyl, pyrimidinyl, pyrrolyl, quinazolinyl, quinolinyl, thiazolyl, thienyl, and tetrazolyl;

R² is selected from phenyl substituted with 0-3 R⁵ and a 5-10 membered heteroaryl system containing 1-4 heteroatoms substituted with 0-3 R⁵, wherein the heteroaryl system is selected from benzimidazolyl, benzofuranyl, benzothiofuranyl, benzoxazolyl, benzthiazolyl, benztriazolyl, benztetrazolyl, benzisoxazolyl, benzisothiazolyl, benzimidazolonyl, cinnolinyl, furanyl, imidazolyl, indazolyl, indolyl, isoquinolinyl isothiazolyl, isoxazolyl, oxazolyl, pyrazinyl, pyrazolyl, pyridazinyl, pyridinyl, pyrimidinyl, pyrrolyl, quinazolinyl, quinolinyl, thiazolyl, thienyl, and tetrazolyl.

6. (Canceled)

7. (Currently Amended) The compound of claim 5[[6]], wherein:

R⁵ is selected from methyl, ethyl, propyl, i-propyl, butyl, i-butyl, s-butyl, pentyl, hexyl, CF₃, CF₂CF₃, CF₂H, OCF₃, Cl, Br, I, F, SCF₃, NR^{5a}R^{5a}, NHC(O)OR^{5a}, NHC(O)R^{5b}, and NHC(O)NHR^{5a}; and

R¹² is selected from H and methyl.

8. (Currently Amended) A compound of claim 7, wherein:

Z is -NHC(O)- or -NHC(S)-, -NHC(O)NH-, -NHC(S)NH-, -NHSO₂-, ~~NR¹⁹-CH₂-~~;

X is -CHR¹⁶NR¹⁷-;

R¹ is selected from phenyl substituted with 0-3 R⁴, and a 5-10 membered heteroaryl system substituted with 0-2 R⁴, wherein the heteroaryl is selected from indolyl, and pyridyl;

R² is phenyl substituted with 0-2 R⁵;

R^3 is selected from $(CRR)_qOH$, $(CRR)_qOR^{3d}$, $(CH_2)_rC(O)OH$, $(CH_2)_rC(O)NR^{3a}R^{3a}$, $(CHR)_rC(O)NR^{3a}OR^{3d}$, $(CH_2)C(O)R^{3b}$, $(CH_2)_rC(O)OR^{3d}$, and (CH_2) -phenyl;

R^{3a} is selected from H, methyl, ethyl, propyl, i-propyl, butyl, i-butyl, s-butyl, t-butyl, allyl, CH_2CF_3 , $C(CH_3)CH_2CH_2OH$, cyclopropyl, 1-methylcyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, phenyl, and benzyl;

R^{3b} is selected from pyrrolidinyl, pyrrolid-3-enyl, and morpholinyl;

R^{3d} is selected from methyl, ethyl, propyl, i-propyl, butyl, i-butyl, t-butyl and benzyl;

R is selected from H, methyl, ethyl, propyl, i-propyl, butyl, i-butyl, s-butyl, pentyl, neopentyl, phenyl and benzyl;

R^4 is selected from methyl, ethyl, propyl, i-propyl, butyl, ethylene, OCH_3 , OCF_3 , SCH_3 , SO_2CH_3 , Cl, F, Br, CN;

alternatively, two R^4 join to form $-O-(CH_2)-O-$;

R^6 is selected from H, methyl, ethyl, propyl, i-propyl, butyl, $C(O)OCH_3$, $C(O)NHCH_2CH_3$;

R^7 is H;

R^{16} is selected from H and methyl;

R^{17} is selected from H and methyl;

m is 0 ;

l is 0

r is 0 or 1; and

q is 1.

9. (Original) The compound of claim 1, wherein the compound is selected from:

N-[(3S)-1-[(1S, 2S)-1-[(2,4-Dimethyl-benzylamino)-methyl]-2-hydroxy-pentyl]-2-oxo-pyrrolidin-3-yl]-3-trifluoromethyl-benzamide;

1-[(3S)-1-[(1S, 2S)-1-[(2,4-Dimethyl-benzylamino)-methyl]-2-hydroxy-pentyl]-2-oxo-pyrrolidin-3-yl]-3-(3-trifluoromethylphenyl)-urea;

{2-[(3S)-1-[(1S, 2S)-1-[(2,4-Dimethyl-benzylamino)-methyl]-2-hydroxy-pentyl]-2-oxo-pyrrolidin-3-ylcarbamoyl]-4-trifluoromethyl-phenyl}-carbamic acid tert-butyl ester;

2-Amino-N-[(3S)-1-[(1S, 2S)-1-[(2,4-dimethyl-benzylamino)-methyl]-2-hydroxy-pentyl]-2-oxo-pyrrolidin-3-yl]-5-trifluoromethyl-benzamide;

3-Amino-N-[(3S)-1-[(1S, 2S)-1-[(2,4-dimethyl-benzylamino)-methyl]-2-hydroxy-pentyl]-2-oxo-pyrrolidin-3-yl]-5-trifluoromethyl-benzamide; and

2-Amino-N-[(3S)-1-[(1S)-1-tert-butylcarbamoyl-2-(2,4-dimethyl-benzylamino)-ethyl]-2-oxo-pyrrolidin-3-yl]-5-trifluoromethyl-benzamide.

10. (Original) A pharmaceutical composition, comprising a pharmaceutically acceptable carrier and a therapeutically effective amount of a compound of claims 1-9.

11. – 13. (Canceled)

14. (Withdrawn) A method for treating disorders, comprising administering to a patient in need thereof a therapeutically effective amount of a compound of claims 1-9, said disorders being selected from osteoarthritis, aneurism, fever, cardiovascular effects, Crohn's disease, congestive heart failure, autoimmune diseases, HIV-infection, HIV-associated dementia, psoriasis, idiopathic pulmonary fibrosis, transplant arteriosclerosis, physically- or chemically-induced brain trauma,

inflammatory bowel disease, alveolitis, colitis, systemic lupus erythematosus, nephrotoxic serum nephritis, glomerulonephritis, asthma, multiple sclerosis, atherosclerosis, rheumatoid arthritis, restinosis, organ transplantation, and cancer.

15. (Withdrawn) The method for treating disorders, of claim 14, wherein said disorders being selected from psoriasis, idiopathic pulmonary fibrosis, transplant arteriosclerosis, physically- or chemically-induced brain trauma, inflammatory bowel disease, alveolitis, colitis, systemic lupus erythematosus, nephrotoxic serum nephritis, glomerulonephritis, asthma, multiple sclerosis, atherosclerosis, rheumatoid arthritis, restinosis, organ transplantation, and cancer.

16. (Withdrawn) The method for treating disorders, of claim 15, wherein said disorders being selected from alveolitis, colitis, systemic lupus erythematosus, nephrotoxic serum nephritis, glomerulonephritis, asthma, multiple sclerosis, atherosclerosis, rheumatoid arthritis, restinosis, organ transplantation, and cancer.

17. (Withdrawn) The method for treating disorders, of claim 16, wherein said disorders being selected from asthma, multiple sclerosis, atherosclerosis, rheumatoid arthritis, restinosis, organ transplantation, and cancer.

18. (Withdrawn) A method for treating rheumatoid arthritis, comprising administering to a patient in need thereof a therapeutically effective amount of a compound of claims 1-9.

19. (Withdrawn) A method for treating multiple sclerosis, comprising administering to a patient in need thereof a therapeutically effective amount of a compound of claims 1-9.

20. (Withdrawn) A method for treating atherosclerosis, comprising administering to a patient in need thereof a therapeutically effective amount of a compound of claims 1-9.

21. (Withdrawn) A method for treating asthma, comprising administering to a patient in need thereof a therapeutically effective amount of a compound of claims 1-9.

22. (Withdrawn) The method for treating disorders of claim 17, wherein said disorders being selected from restinosis, organ transplantation, and cancer.

23. (Withdrawn) A method for treating restinosis, comprising administering to a patient in need thereof a therapeutically effective amount of a compound of claims 1-9.

24. (Withdrawn) A method for treating organ transplantation, comprising administering to a patient in need thereof a therapeutically effective amount of a compound of claims 1-18.

25. (Withdrawn) A method for treating inflammatory diseases, comprising administering to a patient in need thereof a therapeutically effective amount of a compound of claims 1-9.

26. (Canceled)